Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abraxane and Bevacizumab Biosimilar in Recurrent Platinum-Resistant Ovarian Cancer
NCT04670978Phase 2Unknown
- Sponsor
- Shandong University
- Start
- Mar 2021
- Primary completion
- Dec 2023
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nab-paclitaxel in Epithelial Ovarian Cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Shandong University. Status: unknown.
02
Drugs
nab-paclitaxel
03
Conditions
Epithelial Ovarian Cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04670978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04670978.